produits : TG6002

TG6002

TG6002, oncolytic virus

A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the tumor.

TG6002 aims to attack solid tumors on multiple “fronts” while avoiding the side effects of chemotherapy.

This oncolytic virus allows the production of a chemotherapy agent directly in the tumor through the FCU1 gene. The expression of this gene in tumor cells allows the local conversion of orally administered 5-FC into 5-FU, a chemotherapy commonly used in the treatment of certain cancers.   
  Discover how TG6002 works 

 

Sale of the rights in China

Tasly Biopharmaceutical Group Co, Ltd. acquired research, development and commercialization rights of the technology of TG6002 (T601) for Greater China in 2018. >>read the press release

First promising results

Transgene is developing TG6002 for the treatment of several solid tumors, such as gastro-intestinal adenocarcinoma (stomach, pancreas and colon). Phase I interim results demonstrate that after IV infusion, TG6002 was detected in the tumor and induced the production of 5-FU. No major SAE have been observed.

  Poster presented at ESMO 2021 

Attacking the tumor on several fronts

TG6002 combines several mechanisms of action to:

  • directly and selectively destroy the cancer cells (oncolysis) by causing immunogenic cell death;
  • induce an immune response,, following the release of antigens during the oncolysis;
  • allow the production of chemotherapy (5-FU), directly in the tumor..

Ongoing clinical trials

IndicationPhase 
Colorectal cancer – IV routePhase I/IIaMore information
Colorectal cancer – IHA routePhase I/IIMore information

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits